IP Verse

Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer - EP2651442

The patent EP2651442 was granted to University OF Maryland on Apr 22, 2020. The application was originally filed on Dec 14, 2011 under application number EP11849221A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2651442

UNIVERSITY OF MARYLAND
Application Number
EP11849221A
Filing Date
Dec 14, 2011
Status
Granted And Under Opposition
Mar 20, 2020
Grant Date
Apr 22, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJan 21, 2021POTTER CLARKSONADMISSIBLE
AVENCELL EUROPEJan 20, 2021KAILUWEIT & UHLEMANN PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4946778
OPPOSITIONUS2003175288
OPPOSITIONUS2005113561
OPPOSITIONUS2007172504
OPPOSITIONUS2008003225
OPPOSITIONUS2009011984
OPPOSITIONUS2010278830
OPPOSITIONWO0190198
OPPOSITIONWO2012082841

Non-Patent Literature (NPL) Citations (52) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ANG S O, ET AL., "Generating a Chimeric Antigen Receptor to Redirect T-cell Specificity After Infusion, abstr 353", Molecular Therapy, Elsevier Inc., US, US , (20110518), vol. 19, no. SUP. 1, ISSN 1525-0016, page S137, XP003027757-
OPPOSITION- Ang Sonny O. , Cassie Hartline, Tiejuan Mi, Sourindra N. Maiti, George W. Jackson, Helen Hul,1 Elizabeth Shpall, Dean A. Lee, Richard E. Champlin, Laurence J. N. Cooper, "Generating a Chimeric Antigen Receptor to Redirect T-Cell Specificity after Infusion", Mol. Ther., (20110500), vol. 19, no. 1, pages S137 - S138, XP003027757-
OPPOSITION- Anonymous, "Agenda, American Society of Gene & Cell Therapy 14th Annual Meeting", Mol. Ther., (20110518), vol. 19, no. 1, pages 1 - 15, XP055788737-
OPPOSITION- Anonymous, "A Phase II Study of EC 17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma.", Excerpt from U.S. National Library of Medicine. Clinical Trials., (20120308), pages 1 - 7, URL: https://clinicaltrials.gov/ct2/show/NCT00485563, XP055788853-
OPPOSITION- ARCONDEGUY T et al., "VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level", Nucleic Acid Research, (20130000), vol. 41, no. 17, pages 7997 - 8010, XP002784566-
OPPOSITION- BANNANTINE JP et al., "Expression and Immunogenicity of Proteins Encoded by Sequences Specific to Mycobac- terium avium subsp. paratuberculosis", Journal of Clinical Microbiology, (20040000), vol. 42, no. 1, pages 1006 - 1114, XP055788867-
OPPOSITION- BEER TM et al., "Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer", British Journal of Cancer, (20040000), vol. 91, pages 1425 - 1427, XP055788858-
OPPOSITION- BREITZ HB et al., "Clinical optimization of pretargeted radioimmunotherapy with antibody- streptavidin conjugate and 90Y-DOTA-biotin", J. Nucl. Med., (20000000), vol. 41, no. 1, pages 131 - 140, XP000937659-
OPPOSITION- CHO Y et al., "The Cooperative Role of CD 326+ and CD 11b+ Dendritic Cell Subsets for a Hapten-Induced Th2 Differentiation", J. Immunol., (20170000), vol. 199, no. 9, pages 3137 - 3146, XP055788762-
OPPOSITION- Clémenceau B et al., "Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified anti- gen-specific human T lymphocytes", Blood, (20060000), vol. 107, pages 4669 - 4677, XP055788720-
OPPOSITION- DALE GL et al., "Antibodies against biotinylated proteins are present in normal human serum", J. Lab. Clin. Med, (19940000), vol. 123, no. 3, pages 365 - 371, XP055788774-
OPPOSITION- DELAMARRE L et al., "Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis", The Journal of Experimental Medicine, (20060000), vol. 203, no. 9, pages 2049 - 2055, XP055788873-
OPPOSITION- DONDA A et al., " In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts", Cancer Immunity, (20030000), vol. 3, page 11, XP055788792-
OPPOSITION- FERNANDO NH et al., "Targeted Therapy of Colorectal Cancer: Clinical Experi- ence with Bevacizumab", The Oncologist, (20040000), vol. 9, pages 11 - 18, XP055788712-
OPPOSITION- KHAN S et al., "Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of spe- cific CD 8+ T-cells", Mol. Immunol., (20090000), vol. 46, no. 6, pages 1084 - 1091, XP055788783-
OPPOSITION- LAM L et al., "Apparent Hyperthyroidism Caused by Biotin-Like Interference from IgM Anti-Streptavidin Antibodies", Thyroid, (20180000), vol. 28, no. 8, pages 1063 - 1067, XP055788862-
OPPOSITION- LU Y et al., "Folate targeting of haptens to cancer cell surfaces mediates immuno- therapy of syngeneic murine tumors", Cancer Immunol Immunother, (20020000), vol. 51, no. 3, pages 153 - 162, XP055788770-
OPPOSITION- MA Q et al., "Carcinoembryonic antigen- immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA im- munoglobulin-T- cell receptor-modified T cells, representative of a new class of Ig fusion proteins", Cancer Gene Therapy, (20040000), vol. 11, pages 297 - 306, XP055788799-
OPPOSITION- NAKAMURA K et al., "Immune response to a hapten of fluorescein isothiocyanate in a single mouse analyzed by two-dimensional affinity electrophoresis", Electro- phoresis, (19930000), vol. 14, no. 1-2, pages 81 - 87, XP055788755-
OPPOSITION- OGG GS et al., "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes", British Journal of Cancer, (20000000), vol. 82, no. 5, pages 1058 - 1062, XP002215040-
OPPOSITION- RAMSINGH AL et al., "Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation", PLoS ONE, (20180000), vol. 13, no. 6, pages 1 - 20, XP055788876-
OPPOSITION- ROBINSON JH et al., "Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells", Immu- nology, (19920000), vol. 76, no. 4, pages 593 - 598, XP000197431-
OPPOSITION- SCHRAND B et al., "Hapten-mediated recruitment of polyclonal antibodies to tumors engenders anti- tumor immunity", Nat. Commun ., (20180000), vol. 9, no. 1, page 3348, XP055788779-
OPPOSITION- SCHULMAN ES, "Development of a monoclonal anti-immunoglobulin E antibody (omali- zumab) for the treatment of allergic respiratory disorders", Am. J. Respir. Crit. Care Med., (20010000), vol. 164, pages S6 - 11, XP055788715-
OPPOSITION- SILICIANO R et al., "The Interaction of Nominal Antigen with T Cell Antigen Receptors - 1. Specific Binding of Multivalent Nomi- nal Antigen to Cytolytic T Cell Clone", The Journal of Immunology, (19850000), vol. 135, pages 906 - 914, XP055788811-
OPPOSITION- Thakur Archana; Lum Lawrence G, "Cancer therapy with bispecific antibodies: Clinical experience", Curr. Opin. Mol. Ther., (20100600), vol. 12, no. 3, pages 340 - 349, XP009145639-
OPPOSITION- YANG Q et al., "Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population", Anal. Chem., (20160000), vol. 88, no. 23, pages 11804 - 11812, XP055788850-
OPPOSITION- ZABRISKIE JB, ZABRISKIE JB, ZABRISKIE JB, Essential Clinical Immunology, Cambrigde University press, (20080000), pages 1 - 373-
OPPOSITION- ROBERT B et al., "Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes", Eur. J. Immunol., (20000000), vol. 30, doi:10.1002/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R, pages 3165 - 3170, XP001021944
OPPOSITION- SATO T, "Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine", Cancer Immunol. Immunother., (19960000), vol. 43, no. 3, doi:10.1007/s002620050319, pages 174 - 179, XP000953008
OPPOSITION- ANSARI AM et al., "Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiment s", Stem Cell Rev and Rep, (20160000), vol. 12, doi:10.1007/s12015-016-9670-8, pages 553 - 559, XP036069536
OPPOSITION- SCOTT D et al., "Immunogenicity of biotinylated hapten- avidin complexes", Mol. Immunol., (19840000), vol. 21, no. 11, doi:10.1016/0161-5890(84)90115-9, pages 1055 - 1060, XP023852850
OPPOSITION- DERES K et al., "In vivo priming of virus- specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine", Nature, (19890000), vol. 342, no. 6249, doi:10.1038/342561a0, pages 561 - 564, XP002142260
OPPOSITION- CARTELLIERI M et al., "Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts", Blood Cancer J, (20160000), vol. 6, no. 8, doi:10.1038/bcj.2016.61, page e458, XP055532158
OPPOSITION- MORGAN RA et al., "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing Erbb2", Molecular Therapy, (20100000), vol. 18, no. 4, doi:10.1038/mt.2010.24, pages 843 - 851, XP055023624
OPPOSITION- SAVAGE P et al., "Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes", British Journal of Cancer, (20020000), vol. 86, doi:10.1038/sj.bjc.6600223, pages 1336 - 1342, XP002375766
OPPOSITION- PATEL SD et al., "T- cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors", Cancer Gene Therapy, (20000000), vol. 7, no. 8, doi:10.1038/sj.cgt.7700213, pages 1127 - 1134, XP055259929
OPPOSITION- STRIPECKE R et al., "Immune response to green fluorescent protein: implications for gene therapy", Gene Ther- apy, (19990000), vol. 6, doi:10.1038/sj.gt.3300951, pages 1305 - 1312, XP003002920
OPPOSITION- HWU P et al., "Lysis of Ovarian Cancer Cells by Human Lymphocytes Redirected with a Chimeric Gene Composed of an Antibody Variable Region and the Fc Receptor gamma Chain", The Journal of Experimental Medicine, (19930000), vol. 178, doi:10.1084/jem.178.1.361, pages 361 - 366, XP000865656
OPPOSITION- Berry L. J., Moeller M., Darcy P. K., "Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells", TISSUE ANTIGENS., MUNKSGAARD, COPENHAGEN., DK, DK , (20091001), vol. 74, no. 4, doi:10.1111/j.1399-0039.2009.01336.x, ISSN 0001-2815, pages 277 - 289, XP055838046
OPPOSITION- BANDARA NA et al., "Folate-Hapten-Mediated Im- munotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer", Mol. Cancer Ther., (20170000), vol. 16, no. 3, doi:10.1158/1535-7163.MCT-16-0569, pages 461 - 468, XP055646791
OPPOSITION- FOLLENZI A et al., "Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice", Blood, (20040000), vol. 103, no. 10, doi:10.1182/blood-2003-09-3217, pages 3700 - 3709, XP055626883
OPPOSITION- CLEMENCEAU BEATRICE ET AL, "Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes", Blood, American Society of Hematology, US, US , (20060601), vol. 107, no. 12, doi:10.1182/blood-2005-09-3775, ISSN 0006-4971, pages 4669 - 4677, XP002492490
OPPOSITION- Carlos A Ramos, Gianpietro Dotti, "Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy", Expert Opinion on Biological Therapy, (20110701), vol. 11, no. 7, doi:10.1517/14712598.2011.573476, ISSN 14712598, pages 855 - 873, XP055122639
SEARCH- SADELAIN M ET AL, "The promise and potential pitfalls of chimeric antigen receptors", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 21, no. 2, doi:10.1016/J.COI.2009.02.009, ISSN 0952-7915, (20090401), pages 215 - 223, (20090325), XP026058399 [I] 1-14 * page 218, column l, paragraph 1 - column r, paragraph 3; table 1 *
SEARCH- XIAO-SONG ZHONG ET AL, "Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication", MOLECULAR THERAPY, (20100201), vol. 18, no. 2, doi:10.1038/mt.2009.210, ISSN 1525-0016, pages 413 - 420, XP055023623 [X] 1-14 * page 414, column l, paragraph 2 - paragraph 4; figures 1-5 *
SEARCH- RICHARD A MORGAN ET AL, "Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2", MOLECULAR THERAPY, (20100401), vol. 18, no. 4, doi:10.1038/mt.2010.24, ISSN 1525-0016, pages 843 - 851, XP055023624 [I] 1-14 * abstract *
SEARCH- SALIL D PATEL ET AL, "T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors", CANCER GENE THERAPY, GB, (20000801), vol. 7, no. 8, doi:10.1038/sj.cgt.7700213, ISSN 0929-1903, pages 1127 - 1134, XP055259929 [X] 1-14 * abstract *
SEARCH- DAVID T. RODGERS ET AL, "Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20160126), vol. 113, no. 4, doi:10.1073/pnas.1524155113, ISSN 0027-8424, pages E459 - E468, XP055260066 [T] * the whole document *
SEARCH- C.-Y. WU ET AL, "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor", SCIENCE, US, (20151016), vol. 350, no. 6258, doi:10.1126/science.aab4077, ISSN 0036-8075, pages aab4077 - aab4077, XP055260068 [T] * the whole document *
SEARCH- K. URBANSKA ET AL, "A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor", CANCER RESEARCH, US, (20120207), vol. 72, no. 7, doi:10.1158/0008-5472.CAN-11-3890, ISSN 0008-5472, pages 1844 - 1852, XP055260058 [T] * the whole document *
SEARCH- Y. ZHAO ET AL, "A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity", THE JOURNAL OF IMMUNOLOGY, (20091101), vol. 183, no. 9, doi:10.4049/jimmunol.0900447, ISSN 0022-1767, pages 5563 - 5574, XP055081967 [X] 1-14 * page 5564, column l, paragraph 3; figures 5-7 * * page 5571, column l, paragraph 2 - page 5573, column l, paragraph 3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents